

SOURCE: Neptune Technologies & Bioressources Inc.

## Neptune Provides Update on Plant Operating Permits

**Laval, Québec, CANADA – May 8, 2014** – Neptune Technologies & Bioressources Inc. (“Neptune” or the “Corporation”) (NASDAQ.NEPT - TSX.NTB), provided an update today on the status of operating permits for its Sherbrooke, Quebec, Canada plant.

As previously announced, Neptune expects to resume production upon receipt of all outstanding permits for its new production facility. To date, the municipal fire department has approved the plant’s emergency evacuation plan and no further approvals are required from them. In addition, the Minister of Environment is expected to issue its permit upon notification that the Commission de la santé et de la sécurité du travail (“CSST”), the Québec commission overseeing health and safety in the workplace has confirmed the plant conforms to all safety regulations.

During the most recent inspection of the plant by the CSST, certain items were identified that are readily addressable and the facility will be open once the requirements are met. Accordingly, Neptune is targeting an early June 2014 plant opening.

### **About Neptune Technologies & Bioressources Inc.**

Neptune is a biotechnology company engaged primarily in the development and commercialization of marine-derived omega-3 polyunsaturated fatty acids (“**PUFAs**”). Neptune has a patented process of extracting oils from Antarctic krill, and principally sells omega-3 PUFAs as bulk oil to Neptune’s distributors who commercialize them under their private label primarily in the U.S., European and Australian nutraceutical markets. Neptune’s products generally come in bulk oil or capsule form and serve as a dietary supplement to consumers. Neptune’s head office is located at 545 Promenade du Centropolis, Suite 100, Laval, Quebec.

Neptune holds approximately 49% of the participating and voting rights of Acasti Pharma Inc. (“**Acasti**”) and 96% of the voting rights of NeuroBioPharm Inc. (“**NeuroBio**”). Through these subsidiaries, Neptune is also pursuing opportunities in the medical food and prescription drug markets. Acasti and NeuroBioPharm respectively focus on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions. Acasti’s lead prescription drug candidate is CaPre®, a purified high omega-3 phospholipid concentrate derived from Neptune krill oil being developed to address the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, which is characterized by abnormally high levels of triglycerides.

### **Forward Looking Statements**

*Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.*

*The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the “Cautionary Note Regarding Forward-Looking Statements” section contained in Neptune’s latest*

*prospectus supplement, available on SEDAR at [www.sedar.com](http://www.sedar.com) (the “Prospectus Supplement”). All forward-looking statements in this press release are made as of the date of this press release. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the Prospectus Supplement under “Risk Factors”.*

*Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.*

**Neptune Contacts:**

André Godin  
Chief Financial Officer  
+1.450.687.2262  
[a.godin@neptunebiotech.com](mailto:a.godin@neptunebiotech.com)  
[neptunebiotech.com](http://neptunebiotech.com)

John Ripplinger  
Investor Relations  
+1.450.687.2262  
[j.ripplinger@neptunebiotech.com](mailto:j.ripplinger@neptunebiotech.com)  
[neptunebiotech.com](http://neptunebiotech.com)